Targeting a Targeted Drug: An Approach Toward Hypoxia-Activatable Tyrosine Kinase Inhibitor Prodrugs

Tyrosine kinase inhibitors (TKIs), which have revolutionized cancer therapy over the past 15 years, are limited in their clinical application due to serious side effects. Therefore, we converted two approved TKIs (sunitinib and erlotinib) into 2-nitroimidazole-based hypoxia-activatable prodrugs. Kin...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:ChemMedChem
Päätekijät: Karnthaler-Benbakka, Claudia, Groza, Diana, Koblmüller, Bettina, Terenzi, Alessio, Holste, Katharina, Haider, Melanie, Baier, Dina, Berger, Walter, Heffeter, Petra, Kowol, Christian R., Keppler, Bernhard K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151264/
https://ncbi.nlm.nih.gov/pubmed/27706901
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cmdc.201600417
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia